Puma Biotechnology, Inc.
PBYI
$8.83
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 26.08% | -40.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.08% | -40.61% | |||
| Cost of Revenue | 19.68% | -54.93% | |||
| Gross Profit | 28.02% | -34.28% | |||
| SG&A Expenses | -4.75% | 0.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.57% | -16.63% | |||
| Operating Income | 298.15% | -122.38% | |||
| Income Before Tax | 340.59% | -120.03% | |||
| Income Tax Expenses | -82.82% | -91.11% | |||
| Earnings from Continuing Operations | 318.20% | -127.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 318.20% | -127.93% | |||
| EBIT | 298.15% | -122.38% | |||
| EBITDA | 911.98% | -106.56% | |||
| EPS Basic | 317.89% | -127.65% | |||
| Normalized Basic EPS | 340.38% | -119.82% | |||
| EPS Diluted | 316.80% | -128.63% | |||
| Normalized Diluted EPS | 332.78% | -120.29% | |||
| Average Basic Shares Outstanding | 0.19% | 1.00% | |||
| Average Diluted Shares Outstanding | 3.44% | -1.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||